What is Impulse Dynamics?
Impulse Dynamics® is a medical technology company dedicated to improving the lives of patients suffering from heart failure (HF). Its proprietary CCM® (Cardiac Contractility Modulation) therapy, delivered via the Optimizer® technology platform, is designed to enhance the quality of life for individuals with severe HF symptoms who have exhausted other treatment options. The therapy has received regulatory approval for commercial use in both the United States and internationally, demonstrating its established safety and efficacy in addressing a critical unmet medical need.
How much funding has Impulse Dynamics raised?
Impulse Dynamics has raised a total of $470M across 5 funding rounds:
Series A
$30M
Series B
$45M
Debt
$101M
Other Financing Round
$136M
Unspecified
$158M
Series A (2016): $30M with participation from Tcc Capital and Janus Henderson Group
Series B (2017): $45M led by Goldstone Investment
Debt (2022): $101M supported by Squarepoint Capital, Kennedy Lewis Investment Management, Abiomed, and Alger
Other Financing Round (2024): $136M featuring Perceptive Advisors, Alger, and Redmile Group
Unspecified (2025): $158M backed by Redmile Group, Alger, Sands Capital, Braidwell, and Perceptive Advisors
Key Investors in Impulse Dynamics
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
Alger
Fred Alger Management is an independent investment management company. It offers asset management and investment management services. The company was formed in 1964 and is headquartered in New York, New York.
Redmile Group
Redmile Group LLC is a company that operates in the Venture Capital & Private Equity industry. It employs 20to49 people and has 5Mto10M of revenue. The company is headquartered in New York City, New York.
What's next for Impulse Dynamics?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Impulse Dynamics. This capital infusion is expected to accelerate the company's commercial expansion, further research and development into CCM® therapy, and potentially broaden its market reach. The involvement of sophisticated investors like Perceptive Advisors, Alger, and Redmile Group suggests a strategic focus on scaling operations and solidifying its position as a leader in advanced heart failure treatment. Future developments may include expanded clinical trials, new product iterations, and strategic partnerships to enhance patient access to this life-changing therapy.
See full Impulse Dynamics company page
